Fierce Biotech’s Ben Adams focuses on Precision’s acquisition of Applied Immunology.
Establishes Bay Area Immune-Response Laboratory Capability
Bethesda, Md. and Redwood City, Calif., May 3, 2016 – Precision for Medicine, part of the Precision Medicine Group, announced today that it has acquired Applied Immunology, an established expert in the creation and delivery of custom cell-based and immunoassay solutions. Applied Immunology supports innovative and targeted therapeutics developers across all areas, ranging from immuno-oncology to rare diseases to biosimilars from research to post-approval. Applied Immunology’s client base includes some of the most pioneering new venture-backed startups, along with many major global pharmaceutical firms.
Chad Clark is quoted in the pharmaletter regarding the recent acquisition of Applied Immunology.
Carolyn Morgan discusses the rebrand of LehmanMillet to precisioneffect in Medical Marketing & Media.
37-Year-Young Advertising Agency Gets a New Name, New Locations and
Expanded Service Offering
Boston, March 29, 2016 – LehmanMillet, the only healthcare communications agency dedicated to working with companies seeking to change the standard of care, has changed its name to precisioneffect (www.precisioneffect.com). The impetus for the name change was the firm’s acquisition by Precision Medicine Group (PMG) in May of 2015. PMG is a specialized services company supporting next-generation approaches to drug development and commercialization.
Dan Renick comments on the burden of out-of-pocket patient costs for specialty medications in PM360.
Precision for Medicine’s Chad Clark comments on the acquisition of ACT Oncology in Medical Marketing & Media.
Chad Clark and Pat Devitt speak with Ben Adams from FierceBiotech on the acquisition of ACT Oncology.
Establishes leading platform for Precision Medicine Oncology Research
Bethesda, Md. and Flemington, N.J., March 22, 2016 – Precision for Medicine, part of the Precision Medicine Group, announced today that it has executed a binding agreement to acquire ACT Oncology, the leading contract research organization (CRO) specializing exclusively in the field of oncology. ACT Oncology provides drug development services focused on the design and execution of clinical trials on behalf of innovative life sciences companies and not-for-profit patient organizations.
By Ilyssa Levins
R&D Spending by Drug Companies
You may have read my February 2016 PCM article that proposed a six-step plan to deflect criticism about pharmaceutical drug costs. I provided hard data to support the value of our industry and will now continue to expand upon our value by addressing the significant role of America’s biopharmaceutical companies in bringing new medicines to patients. (more…)